cancer Solid tumors
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: The patient will have a histologically or cytologically documented solid tumor The patient will start with antiangiogenic treatment as monotherapy The patient must be >= 18 years of age The patient will have not received any chemotherapy or biological therapy within the last 28 days and has recovered from any acute effects The patients is able to safely donate approximately 120ml of blood in a 6 week period The patient is able to undergo three MRI assessments in a 6 week period
Exclusion criteria
Exclusion criteria: The patient has received treatment within the last 28 days with a drug that has not received regulatory approval for any indication at the time of study entry. Metal implants including a pacemaker, aneurysm clips of stainless steel, implanted insulin pump, cochlea implants, specific heart valves, which are a contraindication for MRI. Metal splinter in the eye Implanted vascular access device is approved if it is not in use. Claustrophobia, not able to undergo MRI. Clinical signs of brain or meningeal metastases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine whether antiangiogenic treatment 1) impairs platelet biology and 2) induces MRI detectable cerebral changes | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) a. growth factor concentrations in platelets, plasma and serum b. Concentration of angiogenesis inhibitors in platelets 2) a. Fatigue score | — |
Countries
Netherlands
Outcome results
None listed